On December 12, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib for the treatment of adult patients with KRASG12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.1